Leung W H, Lau J Y, Chan T K, Kumana C R
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Postgrad Med J. 1989 Jun;65(764):417-9. doi: 10.1136/pgmj.65.764.417.
Mild and self-limiting fever following bleomycin use is common, and a fatal hyperpyrexial response occurs rarely. In previously reported cases, such hyperpyrexia occurred either after the initial administration of the drug or during subsequent therapy following an initial pyrexial response. We describe a fatal hyperpyrexial reaction after bleomycin in a patient with T-cell lymphoma who had had no febrile response when she received her initial injection 3 weeks earlier. Since the occurrence of this hyperpyrexial response is unpredictable, health care workers as well as patients and relatives should always be alert to this potentially lethal complication and prompt measures should be taken in any patient who develops fever after bleomycin use.
使用博来霉素后出现轻度且自限性发热很常见，而致命性高热反应很少发生。在既往报道的病例中，这种高热要么发生在首次用药后，要么发生在首次发热反应后的后续治疗期间。我们描述了1例T细胞淋巴瘤患者在使用博来霉素后发生的致命性高热反应，该患者3周前首次注射时未出现发热反应。由于这种高热反应的发生不可预测，医护人员以及患者和家属应始终警惕这种潜在的致命并发症，并且对于任何在使用博来霉素后发热的患者都应采取迅速措施。
